{"schema":"sb.node.v1","id":"sb:e/9e89b35fd3fb6dc7c4fe34a7","kind":"entity","label":{"text":"easd","locale":"en"},"identity":{"anchor":"label:en:easd","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-10T23:27:45.667496+00:00","snapshot":"deploy 56227b222ea0ec405925ec2672b91c66e5fd51a0"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":37,"separatePublishers":13,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"measured","share":0.676,"named":25,"of":37,"basis":"documents whose own title or summary lead names the subject, over every counted document that mentions it anywhere (the entity graph's measurement); receipts are drawn from the former only"}},"admission":{"state":"provisional","reason":"entity graph provenance 'observed'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-09-23","to":"2026-10-06","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0: about 100% of mentions carry no typed assertion"]}},"dimensions":{"domains":["auto"],"activeDays":9,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":12,"byKind":{"observation":12},"items":[{"id":"sb:o/7b9b689599176cfc234a53df","kind":"observation","label":"Medical Device Network · 2026-10-06 · EASD 2026: MiniMed touts Smart MDI system alert response benefits in type 1 diabetes patients","url":"https://www.medicaldevice-network.com/news/easd-2026-minimed-touts-smart-mdi-system-alert-response-benefits-in-type-1-diabetes-patients/"},{"id":"sb:o/07f99d7f8a650799b64dc4c9","kind":"observation","label":"PR Newswire · 2026-10-04 · SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026","url":"https://www.prnewswire.com/news-releases/sibionics-and-pharmasens-explore-new-horizons-for-automated-insulin-delivery-at-easd-2026-302897720.html"},{"id":"sb:o/246612aa59d61d2b2e01219e","kind":"observation","label":"Clinical Trials Arena · 2026-10-03 · EASD 2026: TRIUMPH-2 data puts retatrutide above the incretin ceiling in T2D","url":"https://www.clinicaltrialsarena.com/analyst-comment/easd-2026-triumph-2-data-retatrutide-t2d/"},{"id":"sb:o/6d65a7cfc27125a064f13c18","kind":"observation","label":"Clinical Trials Arena · 2026-10-03 · EASD 2026: GLP-1 and SGLT2 treatment lowers mortality in heart failure patients","url":"https://www.clinicaltrialsarena.com/analyst-comment/easd-2026-glp-1-sglt2-treatment-lowers-mortality-heart-failure/"},{"id":"sb:o/d2b564991709d5aea6e4afc4","kind":"observation","label":"PR Newswire · 2026-10-02 · Úbytek hmotnosti o 19,3 % ve 48. týdnu: Na EASD byla představena studie fáze III zaměřené na regulaci tělesné hmotnosti s olatorepatidem od Hansoh","url":"https://www.prnewswire.com/news-releases/ubytek-hmotnosti-o-19-3--ve-48--tydnu-na-easd-byla-pedstavena-studie-faze-iii-zamene-na-regulaci-tlesne-hmotnosti-s-olatorepatidem-od-hansoh-302897146.html"},{"id":"sb:o/958bc6327ccf3f61754016c0","kind":"observation","label":"European Medical Journal · 2026-10-02 · Impaired Insulin Sensitivity Linked to Lung Function: EASD 2026","url":"https://www.emjreviews.com/diabetes/news/impaired-insulin-sensitivity-linked-to-lung-function-easd-2026/"},{"id":"sb:o/365612f41626efe4643d256e","kind":"observation","label":"Clinical Trials Arena · 2026-10-02 · EASD 2026: Semaglutide shows promise in treating obesity-related heart failure","url":"https://www.clinicaltrialsarena.com/analyst-comment/easd-2026-semaglutide-shows-promise-in-treating-obesity-related-heart-failure/"},{"id":"sb:o/1fe097df114b5366d82ab126","kind":"observation","label":"Clinical Trials Arena · 2026-10-02 · EASD 2026: Roche’s enicepatide shows 22.7% placebo-adjusted weight loss at 48 weeks","url":"https://www.clinicaltrialsarena.com/analyst-comment/easd-2026-roches-enicepatide-shows-22-7-placebo-adjusted-weight-loss-at-48-weeks/"},{"id":"sb:o/960c9b42d634ff64d7a702db","kind":"observation","label":"Clinical Trials Arena · 2026-10-02 · EASD 2026: Regeneron’s muscle preserver shows benefit at lower doses","url":"https://www.clinicaltrialsarena.com/news/easd-2026-regenerons-muscle-preserver-shows-benefit-at-lower-doses/"},{"id":"sb:o/d62463ff005b4a544d294e5f","kind":"observation","label":"Clinical Trials Arena · 2026-10-02 · EASD 2026: Petrelintide pairs 10.7% weight loss with placebo-like GI tolerability","url":"https://www.clinicaltrialsarena.com/analyst-comment/easd-2026-petrelintide-weight-loss/"}],"cursor":"c1.eyJpZCI6InNiOmUvOWU4OWIzNWZkM2ZiNmRjN2M0ZmUzNGE3IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTEwVDIzOjI3OjQ1LjY2NzQ5NiswMDowMCJ9","order":"newest first; we keep the 12 newest receipts for this entity whose own title or summary lead (the entity graph's test) names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":9,"byKind":{"co-mentioned":9},"items":[{"kind":"relation","label":"co-mentioned with european association (22 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/64f04722c85ebed338bfcedf"},{"kind":"relation","label":"co-mentioned with glp-1 (22 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/7f2792f5b595203cdac0d72c"},{"kind":"relation","label":"co-mentioned with annual meeting (19 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/2e088095ba257d6e7c5d317d"},{"kind":"relation","label":"co-mentioned with italy (18 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/57acc59310eee85f83ace258"},{"kind":"relation","label":"co-mentioned with clinical trials (13 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/fdda46d67aab1fe15914cf6e"},{"kind":"relation","label":"co-mentioned with clinical trial (11 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/b94175eafc6f856e4acaac89"},{"kind":"relation","label":"co-mentioned with unlock free access (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/722131dfee8151b789ff7281"},{"kind":"relation","label":"co-mentioned with drug development (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/e1bd4f2d05f7ccc188c51143"},{"kind":"relation","label":"co-mentioned with hba1c (8 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/4594a40bbf2ab5d93be7a760"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/9e89b35fd3fb6dc7c4fe34a7","mcp":"traverse {\"id\":\"sb:e/9e89b35fd3fb6dc7c4fe34a7\"}","page":"/entity/easd/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/9e89b35fd3fb6dc7c4fe34a7\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/9e89b35fd3fb6dc7c4fe34a7\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/9e89b35fd3fb6dc7c4fe34a7\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/9e89b35fd3fb6dc7c4fe34a7\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}